Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07392450 · ClinicalTrials.gov registry record · Phase 2
A Study of TAK-755 in Adults With Acute Ischemic Stroke
A Phase 2 study, sponsored by Takeda.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
NCT07392450 is a Phase 2 study that is actively recruiting participants, run by Takeda. The registered enrollment target is 222 participants.
The verdict
NCT07392450, a Phase 2 study, is actively recruiting participants, sponsored by Takeda.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
Study Summary
Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occlusion). Strokes can cause serious health problems, death, and affect one's quality of life. To reduce long-term damage, it is important to restore blood flow to the brain as soon as possible. The main aim of this study is to check how safe TAK-755 is, and how well adults with AIS tolerate it. Other aims are to check how well TAK-755 helps participants to manage their everyday activities and to understand whether it helps reduce the seriousness of their stroke symptoms when compared to placebo. A placebo looks like TAK-755, but does not have any medicine in it, to make sure participants do not know which treatment they are taking. The participants will receive TAK-755 or placebo once; afterwards, their health will be monitored for about 3 months (90 days). All participants, regardless of their assignment to either TAK-755 or placebo, will receive the usual treatment for AIS as per the hospital's normal practice.
Interventions
- OTHER Placebo
- BIOLOGICAL TAK-755
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2026-04-07 |
| Est. Completion | 2027-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07392450
The ClinicalTrials.gov registry entry for NCT07392450 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07392450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07392450 about?
NCT07392450 is a clinical study titled "A Study of TAK-755 in Adults With Acute Ischemic Stroke". Acute ischemic stroke (AIS) is a medical emergency that happens because of a sudden stop of blood flow to a part of the brain. This happens when a blood clot forms within the vessel (known as thrombotic occlusion) or a clot originating from somewhere else blocks a blood vessel (known as embolic occl...
What is the current status of trial NCT07392450?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2026-04-07. Estimated completion is 2027-12-06.
What interventions are being tested in trial NCT07392450?
The interventions under investigation include: Placebo (OTHER), TAK-755 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07392450?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.